Name: Latest research reports of Zydus Lifesciences Ltd. authored by Karvy and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Karvy

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

1009.6500 -4.20 (-0.41%)

NSE Sep 08, 2025 15:31 PM

27.00% Gain from 52W Low

Volume: 777.2K

Zydus Lifesciences Ltd.

08 Feb 2020, 12:00AM

1009.65

-0.41%

Cadila Healthcare Ltd: Pharmaceuticals

Buy: Zydus Lifesciences Ltd.

Target

Karvy

We upgrade our Revenues by 1.8%/2.8% in FY20E/FY21E due to upgrade in USand EM business. We downgrade our EBITDAM by 40bps to 18.9% for FY20Ewhile we maintain our EBITDAM for FY21E.

Zydus Lifesciences Ltd. is trading above all available SMAs